Cabozantinib Gets Breakthrough Tx Status for Differentiated Thyroid Cancer
The designation is supported by data from the randomized, double-blind, placebo-controlled phase 3 COSMIC-311 study.
Thyroid Cancer
Exposure to Light at Night May Increase Risk for Thyroid Cancer
Investigators tested the hypothesis that greater exposure to light at night (LAN) is associated with an increased risk for thyroid cancer by studying artificial outdoor LAN measured by satellite imagery in relation to thyroid cancer.
Artificial Light at Night Tied to Thyroid Cancer Risk
Positive association mainly driven by incidence of papillary thyroid cancer.
Thyroid Carcinoma Treatment Regimens
Find information about available non-chemotherapy treatments for thyroid carcinoma, including total thyroidectomy, radiodine treatment, and ablation.
Gavreto Gets Accelerated Approval for RET-Altered Thyroid Cancers
The approval was based on data from the phase 1/2 ARROW trial which evaluated the efficacy and safety of Gavreto in patients with RET-mutant MTC.
RET Inhibitor Demonstrates Efficacy in RET-Altered Thyroid Cancer
Treatment of RET-altered thyroid cancer with selpercatinib, a RET inhibitor, resulted in durable efficacy with a tolerable safety profile in a phase 1/2 trial.
Increasing Trends in Thyroid Cancer Burden Since 1990 Observed Worldwide
Increasing trends in global thyroid cancer burden were observed in a cross-sectional study using data from 195 countries in 21 regions.
Retevmo Gets Accelerated Approval for RET-Driven Lung, Thyroid Cancers
The FDA has granted accelerated approval to Retevmo™ (selpercatinib; Lilly).
Aggressive Subtypes of Papillary Thyroid Cancer Deserve Increased Attention
Although papillary thyroid carcinoma subtypes are often lumped together, mortality risk varied greatly across subtypes.
No Link Found Between Hepatitis C Infection and Extrahepatic Cancers
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
-
Loading...
-
Loading...
